Navigation Links
'Daronrix', Glaxo's Bird-flu Vaccine Approved by European Medicines Agency

London – 'Daronrix', Glaxo's bird-flu vaccine, will hold a pride of place in the annals of preventive medicine, to be the first experimental bird-flu //vaccine to receive certification by the European Medicines Agency, for its use in protecting people in the event of a bird-flu pandemic.

This first generation vaccine can be used only after the WHO or the European Union officially declares a pandemic.

A second –generation vaccine has also been conceived by the same company, Glaxo, and work is underway to study the effects of the vaccine in combating the H5N1 virus strain. The product is slated to go in for approval in the subsequent weeks. This second generation vaccine is intended to strengthen the immune system, as a preventive measure against an imminent pandemic.

The vaccine is doubly beneficial as it has been developed necessitating lesser quantity of antigen to elicit a powerful immune response, which will allow the production of the vaccine in huge quantities, especially beneficial during mass vaccination programmes.
SA
'"/>




Page: 1

Related medicine news :

1. Acid Test - Glaxos Cervarix, and Mercks Gardasil, Compete
2. H5N1 Bird-flu Confirmed in France
3. Hungry for respite: Bird-flu virus ruffles poultry in Hungary
4. Intelligent Ways to Prevent a Bird-flu Outbreak
5. Thai’s Health Ministry Stocked To Deal With Any Possible Bird-flu Outbrea
6. Bird-flu Vaccine Adjuvant Contract Goes to Novartis
7. Vaccine to quit smoking?
8. First Vaccine Designed for Africa Cleared for Testing in Humans
9. Vaccine for Alzheimer’s diseas
10. Health Officials Recommend Flu Vaccine
11. Smallpox Vaccine May Help Fight Cervical Cancer
Post Your Comments:
(Date:7/25/2008)... Authority offers patients consumers tips and enco...nt safety, HARRISBURG, Pa., July 25 /PRNewswire-U...ority today supports "National Patient Safety Day"...and their families to,participate fully in their h...ing they can about their surgery or illness., "We...
(Date:7/25/2008)... - 180-Days of Marketing Exclusivity Begin...l/ -- Watson,Pharmaceuticals, Inc. (NYSE: WPI ), ...ced today that its subsidiary has commenced commer...psules USP product in the 40mg,strength from its D...on,with the launch, Watson has 180 days of marketi...
(Date:7/25/2008)...ck to benefit ALS Therapy Alliance to be presented...ight, WOONSOCKET, R.I., July 25 /PRNewswire/ -- C...raised a record-breaking $4.4 million in just 21 d...gn for ALS research. This is,the seventh year of t...aised more than $15 million for ALS research. This...
(Date:7/25/2008)... The Retina Group of New York wi...lated macular degeneration especially designed for...ale Public Library at 116 Merritts Road, Farmingda...15. Attendance is free and refreshments will be pr...516) 939-6100. , Hicksvil...
Breaking Medicine News(10 mins):Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3
...ined that the deadly Human Immune Deficiency Virus...accine used in Africa in the 1950s and say rumours...ce to back them up. The studies, from researchers ...d help free the polio vaccine manufactured by the ...
... most painful and bothering one is the trauma of g... according to many diabetics is the finger stick. ...p to six times a day for more than ten to twenty y...he pain and discomfort associated with them. But r...
...hursday that plans are afoot to consider listing o...n the US bourses after 2002," Pratap C Reddy, chai... was a part of the business plan for the post-2002...available at the moment, Dr. Reddy added that plan...
... can be prevented if the patients and their doctor...ng to WHO, around 150 million people suffer from a...o the disease every year. Asthma is a chronic resp...t is characterized by sudden recurring attacks of ...
Other Medicine News:
(Date:7/24/2008)...-FirstCall/ -- Alexza,Pharmaceuticals, Inc. (Nasda...ts second Phase 3 clinical trial with AZ-004 (Stac... candidate being developed for the treatment,of ac...polar disorder.,Alexza believes the novel, non-inv...ties resulting from inhaled loxapine administratio...
(Date:7/24/2008).../ -- Headlines claiming "soy,products lower sperm ...e,preliminary study that Dr. Jorge Chavarro, publ...collected intake of soyfoods and not on,specific d...d by many,issues, thus I feel the results should b... Tammy Hedlund, a researcher in prostate cancer,pr...
(Date:7/24/2008)... body temperature, for home,and clinical use, WES...-Med, Inc.,(subsidiary of American Scientific Reso...ibutor of the Thermofocus(R) 5-in-1 non-contact,th... clinical study,conducted by the Second Children,s...y, which proves that the Thermofocus(R) measures b...
(Date:7/24/2008)...ire-FirstCall/ -- NicOx S.A.,(Euronext Paris: COX)...week,open label safety extension that was conducte...y for naproxcinod. The results revealed no unexpec...r the one-year duration of,the study, as measured ...ion, the results showed that the patients, mean bl...
Breaking Medicine Technology:Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6Soyfoods Do Not Impact Sperm Count 2Pediatric Study Finds 21st Century Non-Contact Thermometer as Accurate as Conventional Thermometers 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Armed beetles find a mate whatever their size 2646 1Small Business Health Care Survey Points to Need for Reform 15325 1Small Business Health Care Survey Points to Need for Reform 15325 2Clarient to Present at the B Riley 26 Co 9th Annual Las Vegas Investor Conference 15320 1Clarient to Present at the B Riley 26 Co 9th Annual Las Vegas Investor Conference 15320 2Patient Experience Expert to Present The Power of Wow 21 in Health Care Service Delivery 4227 1Patient Experience Expert to Present The Power of Wow 21 in Health Care Service Delivery 4227 2
...PRNewswire/ -- Asenapine -- an,investigational dru... business unit of Akzo Nobel, for bipolar I disord...e effective than placebo,in treating acute manic a...er, according to new Phase III results, from a stu...on,s 2007 Annual,Meeting. , In the three-week stud...
...ent Reduction in Risk of Hospitalization,from Croh...Ill., May 22, 2007 /PRNewswire-FirstCall/ -- Abbot... of a pivotal study,presented at the Digestive Dis...ng patients with moderate to severely active,Crohn...ntenance,therapy were almost 60 percent less likel...
Other Medicine Technology:Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 2Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 3Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 4New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 2New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 3New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 4New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 5New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 6New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 7
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
Medicine Products: